Sunitinib (Sutent): targets multiple receptor tyrosine kinases, including VEGFR, and has shown potential in reducing tumor growth and metastasis in pancreatic cancer (Doi et al., 2012). Here, NTRK1 is linked to familial pancreatic carcinoma.